Innovent Biologics’ experimental weight-loss drug achieves breakthrough in Phase 3 trial
Innovent plans to soon submit a new drug application (NDA) to China’s National Medical Products Administration
Innovent plans to soon submit a new drug application (NDA) to China’s National Medical Products Administration
Both companies will jointly execute development and scale-up of multiple strategic APIs, including late-stage NCE-1 opportunities
The issue comprises a fresh issue of Rs. 95 crore and targeting a total raise of around Rs. 895 crore
The patent will lock in broad protection for the company’s lead therapy CardiolRx and its novel subcutaneous candidate CRD-38
The study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in invasive disease-free survival
Developed in partnership with the Johns Hopkins Applied Physics Laboratory (APL), the module is built around a multi-segment RT-PCR method with integrated indexing
Under the agreement, Evonik will distribute InVitria’s blood-free rHSA portfolio to its biopharma customers
Merus has licensed Halozyme’s proprietary ENHANZE technology to develop and commercialize subcutaneous formulations of petosemtamab
Subscribe To Our Newsletter & Stay Updated